In tumor mice, an antibody targeting CD36 showed that 15% of metastases (lymph node and lung metastases) achieved a complete response (CR), and mice that had developed lymph node metastases had an 80–90% reduction in lesion size, with little effect on the primary tumor (43). Here, CD36 is linked to neoplasm.